Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea

Equality Impact Assessment (Guidance development) (PDF 145 KB)

Final draft guidance

Public committee slides (PDF 611 KB)

Final appraisal document (PDF 279 KB)

Committee papers (PDF 4.38 MB)

Final scope (PDF 256 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 367 KB)

Equality impact assessment (Scoping) (PDF 171 KB)

Final stakeholder list (PDF 260 KB)

Draft scope pre referral (PDF 342 KB)

Draft matrix pre referral (PDF 261 KB)